Management of diabetes and dementia

Amar Puttanna, Noushad Kulambil Padinjakara

Abstract


Continued advances in medicine have contributed to an ageing population in most countries, with a resultant increased prevalence of dementia as well as type 2 diabetes. Consequently, the combined co-morbidity of diabetes and dementia is on the increase. While there is a wealth of therapeutic options for diabetes in general, we need to adapt these medications and strategies to suit those with dementia. The intricacies of managing diabetes in patients with cognitive dysfunction are multiple and require a sound understanding of the patient, living environment and available therapeutic options. With the exception of metformin, dipeptidyl peptidase-4 inhibitors and to some extent insulin secretagogues, non-insulin therapy has a limited role. Insulin therapy, if initiated with a specified goal in mind and concentration on avoidance of hypoglycaemic episodes with relatively lax glycaemic targets, is the most straightforward way of managing glycaemia. Therapy should be individualised with involvement of the patient’s care team and clear instructions to define roles, goals of therapy and need for regular review. In this article we discuss the effect of dementia on diabetes management and vice versa, glycaemic goals based on available evidence and recommendations including drug and regime selection to safely achieve this. ve this.

Keywords


diabetes mellitus; dementia; oral hypoglycaemic agents; cognitive decline

Full Text:

HTML PDF

References


 Yaffe K, Falvey C, Hamilton N, et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 2012;69:1170-5. http://dx.doi.org/10.1001/archneurol.2012.1117

 Diabetes Control and Complication Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007;356:1842-52. http://dx.doi.org/10.1056/NEJMoa066397

 Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycaemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors. The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial. Diabetes Care 2009;32:221-6. http://dx.doi.org/10.2337/dc08-1153

 Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycaemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565-72. http://dx.doi.org/10.1001/jama.2009.460

 Asvold BO, Sand T, Hestad K, et al. Cognitive function in type 1 diabetic adults with early exposure to severe hypoglycaemia. A 16 year follow up study. Diabetes Care 2012;33:1945-7. http://dx.doi.org/10.2337/dc10-0621

 Diabetes UK. Good Clinical Practice Guidelines for Care Home Residents with Diabetes. A revision document prepared by a Task and Finish Group of Diabetes UK, January 2010. https://www.diabetes.org.uk/Documents/About%20Us/Our%20views/Care%20recs/Care-homes-0110.pdf (accessed 10th September 2016)

 International Diabetes Federation. Managing Older People With Type 2 Diabetes: Global Guideline. 2013. https://www.idf.org/e-library/guidelines/78-global-guideline-for-managing-older-people-with-type-2-diabetes.html (accessed 6th September 2017)

 Sinclair AJ, Hillson R, Bayer AJ, on behalf of a National Expert Working Group. Diabetes and dementia in older people: a Best Clinical Practice Statement by a multidisciplinary National Expert Working Group. Diabet Med 2014;31:1024-31. http://dx.doi.org/10.1111/dme.12467

 Alzheimer’s Disease International. World Alzheimer Report. The Global Impact of Dementia: an Analysis of Prevalence, Incidence, Cost and Trends. 2015. https://www.alz.co.uk/research/WorldAlzheimerReport 2015.pdf (accessed 6th September 2017)

 Diabetes: Facts and Stats Version 4, revised May 2015. https://www.diabetes.org.uk/Documents/Position%20statements/Facts%20and%20stats%20June%202015.pdf (accessed 29 Aug 2015).

 American Diabetes Association. Statistics about Diabetes: Overall Numbers, Diabetes and Prediabetes. http://www.diabetes.org/diabetes-basics/statistics/?loc=superfooter (accessed 26 Aug 2015)

 Travis SS, Buchanan RJ, Wang S, et al. Analyses of nursing home residents with diabetes at admission. J Am Med Dir Assoc 2004;5:320-7.

 Bruce DG, Davis WA, Casey GP, et al. Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the Fremantle Diabetes Study. Diabetologia 2009;52:1808-15. http://dx.doi.org/10.1007/s00125-009-1437-1

 Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycaemia in type 2 diabetes. Post hoc epidemiological analysis of the ACCORD trial. Diabetes Care 2012;35:787-93. http://dx.doi.org/10.2337/dc11-1855

 Lekarcyk JA, Himmel L, Munshi M. Blood glucose monitoring and underlying question of hypoglycaemia are both essential to preventing hypoglycaemia in nursing home residents. Clin Diabetes 2013;31(1).

 Ikeda M, Brown J, Holland AJ, et al. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002;73:371-6.

 Feil DG, Rajan M, Soroka O, et al. Risk of hypoglycemia in older veterans with dementia and cognitive impairment: implications for practice and policy. J Am Geriatr Soc 2011;59:2263-72. http://dx.doi.org/10.1111/j.1532-5415.2011.03726.x

 Davydow DS, Zivin K, Katon WJ, et al. Neuropsychiatric disorders and potentially preventable hospitalizations in a prospective cohort study of older Americans. J Gen Intern Med 2014;29:1362-71. http://dx.doi.org/10.1007/s11606-014-2916-8

 Phelan EA, Borson S, Grothaus L, et al. Association of incident dementia with hospitalizations. JAMA 2012;307:165–72. http://dx.doi.org/10.1001/jama.2011.1964

 Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62(Suppl 27):15-26; discussion 40-1.

 Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62(Suppl 23):30-8.

 Sommerfield AJ, Deary IJ, Frier BM. Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care 2004;27:2335-40.

 Gerstein HC, Miller ME, Byington RP, et al, on behalf of Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59. http://dx.doi.org/10.1056/NEJMoa0802743

 American Diabetes Association. Section 10. Older adults. Standards of Medical Care in Diabetes. 2015. Diabetes Care 2015;38(Suppl 1): S67-S69. https://doi.org/10.2337/dc15-S013

 TREND-UK/IDOP. Diabetes and Dementia Guidance on Practical Management. https://www.diabetes.org.uk/Documents/Professionals/Professional%20resources/Diabetes_And_Dementia_Guidance_2013.pdf (accessed 1 June 2017).

 Evans JG, Sastre AA. Effect of the treatment of type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 2003(1).

 Imfield P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs and risk of Alzheimer’s disease: a population based case control study. J Am Geriatr Soc 2012;60:916-21.

 Alagiakrishnan K, Sankaralingam S, Ghosh M, et al. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer’s disease. Discov Med 2013;16:277-86.

 Maurer MS, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long term care facility. J Gerontol A Biol Sci Med Sci 2005;60:1157-62.

 Shaw FE. Falls in cognitive impairment and dementia. Clin Geriatr Med 2002;18:159-73.

 Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27:1265-70.

 Kristensen JS, Frandsen KB, Bayer T, et al. Compared with repaglinide, sulfonylurea treatment in type 2 diabetes is associated with a 2.5-fold increase in symptomatic hypoglycemia with blood glucose levels <45 mg/dl (abstract). Diabetes 2000;49(Suppl 1):A131.

 Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99.

 Boyle PJ, Zrebiec J. Impact of therapeutic advances in hypoglycemia in type 2 diabetes. Diabetes Metab Res Rev 2008;24:257-85. http://dx.doi.org/10.1002/dmrr.795

 ClinicalTrials.gov. Cognitive dysfunction and glucagon-like peptide-1 agonists. https://clinicaltrials.gov/ct2/show/NCT02423824 (accessed 29 Aug 2015).

 Li Y, Duffy KB, Ottinger MA, et al. GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis 2010;19:1205-19. http://dx.doi.org/10.3233/JAD-2010-1314

 Hölscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 2012;26:871-82. http://dx.doi.org/10.2165/11635890-000000000-00000

 Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007(2). http://dx.doi.org/10.1002/14651858.CD005613.pub3

 Abbatecola AM, Bo M, Barbagallo M, et al. Severe hypoglycaemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study. J Am Med Dir Assoc 2015;16:349.e7-12. http://dx.doi.org/10.1016/j.jamda.2014.12.014




DOI: https://doi.org/10.15277/bjd.2017.139

Refbacks

  • There are currently no refbacks.


The Journal of the Association of British Clinical Diabetologists